FRBRX: Franklin Biotechnology Discovery R6

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

FRBRX Franklin Biotechnology Discovery R6


Profile

FRBRX - Profile

Vitals

  • YTD Return -9.8%
  • 3 Yr Annualized Return -1.2%
  • 5 Yr Annualized Return -6.1%
  • Net Assets $1.13 B
  • Holdings in Top 10 46.9%

52 WEEK LOW AND HIGH

$141.80
$117.45
$169.93

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.70%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 28.62%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $1,000,000
  • IRA N/A

Fund Classification


Distributions

  • YTD Total Return -9.8%
  • 3 Yr Annualized Total Return -0.4%
  • 5 Yr Annualized Total Return -3.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.30%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    May 01, 2013
  • Shares Outstanding
    53439
  • Share Class
    Retirement
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.


Categories

Performance

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD -9.8% -29.6% 0.0% 41.54%
1 Yr -9.5% -34.1% 18.7% 73.73%
3 Yr -1.2%* -14.6% 13.3% 66.67%
5 Yr -6.1%* -12.9% 5.8% 77.45%
10 Yr N/A* -4.0% 13.0% 13.19%

* Annualized

Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2019 24.2% 5.7% 55.4% 23.93%
2018 -18.2% -25.3% 21.5% 88.29%
2017 16.6% -10.8% 43.9% 46.79%
2016 -20.6% -31.6% 6.9% 75.47%
2015 -2.4% -20.4% 13.8% 55.45%

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD -9.8% -29.6% 0.0% 41.54%
1 Yr -9.5% -34.1% 18.7% 73.73%
3 Yr -0.4%* -14.6% 16.2% 70.27%
5 Yr -3.1%* -12.9% 11.2% 61.76%
10 Yr N/A* -4.0% 15.7% 18.68%

* Annualized

Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2019 24.2% 5.7% 55.4% 23.93%
2018 -18.2% -25.3% 22.2% 89.19%
2017 19.3% -10.8% 45.8% 52.29%
2016 -16.8% -26.4% 8.7% 70.75%
2015 6.1% -16.6% 15.2% 49.50%

NAV & Total Return History


Holdings

FRBRX - Holdings

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Assets 1.13 B 1.6 M 41.3 B 45.38%
Number of Holdings 79 26 390 63.08%
Net Assets in Top 10 531 M 141 K 19.7 B 42.31%
Weighting of Top 10 46.88% 21.6% 76.3% 28.46%

Top 10 Holdings

  1. Vertex Pharmaceuticals Inc 6.41%
  2. Biogen Inc 5.93%
  3. Amgen Inc 5.83%
  4. Gilead Sciences Inc 5.25%
  5. Regeneron Pharmaceuticals Inc 5.02%
  6. Illumina Inc 4.13%
  7. Iovance Biotherapeutics Inc 4.12%
  8. PTC Therapeutics Inc 3.64%
  9. GW Pharmaceuticals PLC ADR 3.47%
  10. Deciphera Pharmaceuticals Inc 3.09%

Asset Allocation

Weighting Return Low Return High FRBRX % Rank
Stocks
95.65% 58.15% 102.77% 87.69%
Cash
4.11% -0.01% 41.85% 10.77%
Other
0.23% -2.77% 7.62% 30.77%
Preferred Stocks
0.00% 0.00% 1.02% 83.08%
Convertible Bonds
0.00% 0.00% 0.40% 80.77%
Bonds
0.00% -0.01% 14.94% 82.31%

Stock Sector Breakdown

Weighting Return Low Return High FRBRX % Rank
Healthcare
99.91% 61.99% 100.00% 51.54%
Energy
0.09% 0.00% 0.44% 2.31%
Utilities
0.00% 0.00% 0.00% 80.77%
Technology
0.00% 0.00% 15.59% 80.77%
Real Estate
0.00% 0.00% 6.65% 82.31%
Industrials
0.00% 0.00% 1.89% 80.77%
Financial Services
0.00% 0.00% 3.59% 84.62%
Communication Services
0.00% 0.00% 5.79% 80.77%
Consumer Defense
0.00% 0.00% 34.06% 80.77%
Consumer Cyclical
0.00% 0.00% 5.00% 80.77%
Basic Materials
0.00% 0.00% 2.08% 80.77%

Stock Geographic Breakdown

Weighting Return Low Return High FRBRX % Rank
US
85.91% 49.84% 100.00% 31.54%
Non US
9.74% 0.00% 42.53% 78.46%

Expenses

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.70% 0.10% 9.84% 94.49%
Management Fee 0.59% 0.09% 1.30% 19.23%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.40% 75.00%

Sales Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 28.62% 5.00% 341.00% 21.26%

Distributions

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank
Dividend Yield 0.00% 0.00% 6.04% 82.31%

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Annually Annually

Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Income Ratio -0.30% -2.24% 2.12% 61.42%

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

FRBRX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

22.56

22.6%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

1.58

1.6%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.

Akiva Felt


Start Date

Tenure

Tenure Rank

Jan 27, 2020

0.18

0.2%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.18 22.56 10.01 19.93